Antibody-Drug Conjugate Promising for Breast Cancer With Bra

High intracranial response rates with trastuzumab-deruxtecan observed in TUXEDO-1 trial

Related Keywords

Austria , Vienna , Wien , Berlin , Germany , Massachusetts , United States , Barcelona , Comunidad Autonoma De Cataluna , Spain , Rupert Bartsch , Mike Bassett , Mafalda Oliveira , Hebron University Hospital , Breast Cancer Congress , University Of Vienna , Medical University , European Society , Medical Oncology Breast Cancer Congress ,